Found "Health Policies": 1,019 results
Co-production of evidence for policies in Thailand: from concept to action
KEY MESSAGES
• Thailand uses co-production of evidence, based on the concept of the “triangle that moves the mountain,” to support health policy making
• The annual national health assembly is a key platform for interactions between multiple stakeholders to adopt resolutions through consensus
•
Telemedicine utilization patterns and implications amidst covid-19 outbreaks in Thailand under public universal coverage scheme
Abstract
During COVID-19 pandemic, telemedicine was a strategy to facilitate healthcare service delivery minimizing the risk of direct exposure among people. In Thailand, the National Health Security Office has included telemedicine services under the Universal Coverage Scheme to support social d
Crystal balling into the future: Insights from PMAC side meeting on modelling
On January 23rd, just one day after joining HITAP, I was presented with an opportunity to travel to Bangkok for the renowned annual Prince Mahidol Award Conference (PMAC). The PMAC 2024, hosted at the Centara Grand & Bangkok Convention Centre from January 22nd-27th, 2024, proved to be an enlight
Impact of obesity on economics and quality of life in Thailand (in Thai language)
Impact of obesity on economics and quality of life in Thailand Obesity is regarded as a disease that requires appropriate treatment. At the global level, obesity is ranked the 6th among factors that cause diseases. The economic impact of obesity is substantial. The objective of this study was to estimate that healthcare cost and cost of productiv
Advanced health biotechnologies in Thailand: State of the art, future trends and strategic preparation
Aiming at appropriate preparation for the future development of individualized and regenerative medicine (in particular, gene, stem cell and tissue engineering therapies), the Health Intervention and Technology Assessment (HITAP) program has agreed to conduct a study to provide an insight on elements necessary for national policymaking in Thailand.
Institutionalizing Evidence-Informed Priority Setting for Universal Health Coverage: Lessons From Indonesia
Abstract
Planning and administering Universal Health Coverage (UHC) policies involve complex and critical decisions, especially in resource-scarce and densely populated settings such as Indonesia. Increasing investments alone do not ensure success and sustainability of UHC, and defining prioritie
Understanding healthcare demand and supply through causal loop diagrams and system archetypes: policy implications for kidney replacement therapy in Thailand
Abstract
Background
Systems thinking approaches can determine system interdependencies to guide effective policymaking but have been underutilised in health policymaking, particularly for policies related to access and delivery of health services. In Thailand, a policy changing access to dialysi
Understanding healthcare demand and supply through causal loop diagrams and system archetypes: policy implications for kidney replacement therapy in Thailand
Abstract
Background
Systems thinking approaches can determine system interdependencies to guide effective policymaking but have been underutilised in health policymaking, particularly for policies related to access and delivery of health services. In Thailand, a policy changing access to dialy
Early Career Path: Reflection from the Infectious Disease Modelling (IDM) Conference 2024
I would like to express my gratitude for the opportunity and the support from the UNITE initiative under the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (PMU-B) to be part of the panel discussion at the “Early Career Path” session during the I
Glaxo Agrees to Pay $3 Billion in Fraud Settlement
In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, f
10 / Page